AMCR — Amcor plc

The market is genuinely split, not apathetic. Bulls point to the defensive 0.595 beta, the 5.8% dividend, FY26 adjusted EPS of $4.02 hitting the top of guidance, and Berry synergies running roughly 10% ahead of plan. Bears point to the tape: -6.27% in the week and -9.11% in the month ending 2026-09-13, RSI at 31.88, and JPMorgan's early-September downgrade to Neutral (target moved $44 to $47) on concerns that divestitures will slow medium-term growth. Analyst ratings are 8 Buy / 5 Hold / 1 Sell with a $48.38 consensus target, so the sell-side is constructive while the price action is clearly not — a standoff between income buyers and growth skeptics.

The three-year quarterly series is really two different companies split by the Berry Global close in mid-2025. Pre-merger Amcor ran ~$3.25-3.54B of quarterly revenue with gross margins of 18-21% and operating income of $242-395M. Post-close, revenue steps up to $5.08B (2025-06-30) and then grinds to $5.75B, $5.45B, $5.91B and $6.40B — so the headline +25.9% YoY in fiscal Q4 2026 is almost entirely inorganic, not organic acceleration. The more useful read is margin and EPS recovery off the distorted trough: the 2025-06-30 quarter printed just $87M of operating income and -$0.12 EPS (integration/impairment noise), and the four quarters since have delivered $0.57, $0.38, $0.60 and $0.83 of diluted EPS, with the newest quarter showing gross margin of 25.2% (versus 17.6-19.6% in the prior four) and operating income of $497M. Operating margin is still thin and range-bound at 7.7-8.9%, so this is a stabilising-and-modestly-inflecting story driven by cost synergies, not a structural growth inflection.

On trailing GAAP numbers Amcor looks merely average — P/E TTM 17.71x on EPS of $2.388. But that GAAP figure is heavily loaded with Berry amortization and integration charges; on FY26 adjusted EPS of $4.02 the stock was at 10.5x as of 2026-09-13, and on FY27 consensus of $4.416 it is at 9.6x. PEG is 0.517, EV/EBITDA is 9.97x, and P/S of 0.832 sits well below the 5-year average of 1.03, against a 5-year average P/E of 20.63x — which is why the deterministic model tags it 'Cheap vs. its own history.' The discount is not a free lunch: ~3.9x net debt/EBITDA ($12.7B net debt against ~$3.2B EBITDA) and a 5.4% ROIC justify a structurally lower multiple than pre-merger Amcor earned.

The market is pricing the balance sheet and the trailing GAAP number, not the forward adjusted number. At $42.32 the stock embeds roughly 10.5x FY26 adjusted EPS and a 5.8% yield — a multiple that says 'we believe the leverage and the low ROIC, and we don't yet believe the synergy tail.' If FY27 EPS of $4.416 plus the remaining ~$365M of Berry synergies land, there is a credible path to an 11-12x multiple and $48-52; if divestitures eat into reported revenue and organic volumes stay flat (JPMorgan's concern), the multiple stays stuck at 9-10x and the dividend becomes the entire return. The Nov 4, 2026 fiscal Q1 2027 print (~$1.02 consensus EPS) is the next real evidence point.

As of 2026-09-13 the technical setup is oversold-within-an-uptrend, not broken. RSI stood at 31.88, just shy of the 30 oversold line; the price was -7.90% versus its 20-day SMA, -6.64% versus its 50-day, but only -1.06% versus its 200-day — meaning a six-month advance (+4.31% over 6 months, +4.24% over 3 months) has been given back quickly rather than a long-term trend being violated. The stock at $42.32 sits mid-range in a 52-week band of $36.25-$50.94, about 35% above the low and 17% below the high. Practical implication: this is a legitimate accumulation zone for income buyers near 200-day support, but with short-term momentum clearly down, scaling in is more sensible than a single entry, and a close below roughly $40 would signal the 200-day support thesis has failed.

• Raw material inflation: oil volatility and Middle East conflict drive resin and petrochemical input costs, which hit Amcor's margins before contractual pass-through resets — a real gross-margin timing risk in FY27.
• Rates and defensive rotation: elevated bond yields have pulled money out of low-beta dividend names; Amcor's 0.595 beta cushions drawdowns but also caps upside in risk-on rotations, and its 5.8% yield competes directly with Treasury yields.
• EU Packaging and Packaging Waste Regulation (PPWR) and single-use plastics rules: a compliance cost for the industry, but Amcor is positioning CleanStream recycling and AmPrima recycle-ready structures as a conversion opportunity with brand owners.
• End-market volume softness: packaging demand tracks brand-owner volumes in food, beverage, beauty and healthcare, and the 'slow beauty'/refill shift reshapes mix rather than growing total volumes much.
• Sector consolidation and portfolio pruning: Amcor's ongoing divestitures shrink the reported revenue base, which is exactly the dynamic JPMorgan cited when downgrading the name in early September 2026.

• Fiscal Q1 2027 results on November 4, 2026, with consensus around $1.02 EPS — the first genuinely clean read on organic volumes and post-integration margin structure.
• Berry synergy progression toward the $650M three-year target, with roughly $285M captured in FY26 and realisation tracking about 10% ahead of schedule; each incremental tranche drops largely straight to margin.
• Dividend durability and growth: the $0.65 quarterly dividend payable September 24, 2026 implies a 5.8% yield at $42.32, covered ~72% by FY26 free cash flow of ~$1.57B — an increase or a formal capital-return framework would be a positive catalyst.
• Portfolio divestiture announcements and the market's read on whether they simplify the story or (per JPMorgan) dilute medium-term growth.
• Insider signal: CEO Peter Konieczny's open-market purchase of a net 10,541 shares in early September 2026 is a small but directionally useful vote of confidence near the lows.

• Leverage: $13.83B of long-term debt against $11.79B of equity (D/E 1.279) and roughly 3.9x net debt/EBITDA leaves very little room for an earnings miss before the dividend and buyback capacity come under scrutiny.
• Integration execution on Berry — one year in, the business still runs an 8.1% operating margin and 4.7% net margin, so the synergy case is real but not yet proven at the run-rate level.
• Structurally low returns: ROIC of 5.4% and ROE of 9.4% are below what a 10-11x multiple implies, making a durable re-rating hard to justify on fundamentals alone.
• Weak organic growth masked by acquisition math and now by divestitures, exactly the concern behind the early-September 2026 JPMorgan downgrade.
• Dividend coverage of ~72% of FY26 free cash flow ($1.13B paid against ~$1.57B generated) leaves limited cushion if resin costs spike or volumes soften.

Amcor is a cheap, high-yielding, genuinely defensive packaging compounder whose cheapness is partly earned and partly transitional. The dividend is well covered, the Berry synergies are running ahead of plan, and at 9.6x FY27 consensus EPS with a 5.8% yield there is real total-return potential if the integration keeps delivering. But with 5.4% ROIC, ~3.9x net leverage and inorganic-only top-line growth, a re-rating requires proof rather than narrative, and the tape as of 2026-09-13 is negative. This is a reasonable income holding and an acceptable risk/reward at $42.32 — not a compelling growth story, and not a stock to chase.

I applied an 11.0x forward adjusted P/E to FY27 consensus EPS of $4.416 (11.0 x 4.416 = $48.58), justified as roughly a 45-50% discount to Amcor's 5-year average P/E of 20.63x to reflect the post-Berry ~3.9x net debt/EBITDA, 5.4% ROIC and modest organic growth, offset by the 0.595 beta and a 5.8% dividend yield covered ~72% by free cash flow. Cross-checking with a 10.5x EV/EBITDA multiple on ~$3.24B of TTM EBITDA less $12.72B of net debt gives ~$46.10 per share; blending the two methods and rounding yields $47.50, about 12% above the $42.32 price on 2026-09-13 and modestly below the $48.38 analyst consensus.